ADC Therapeutics Expands Team

Sept 30, 2014
ADC Therapeutics (ADCT, a portfolio company of Auven Therapeutics) the oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced a significant expansion of its team as its first ADCs enter clinical development.
Read the full press release

Transparency Life Sciences to Conduct Sarcoidosis Trial for Auven Therapeutics' KIACTA using Crowdsourcing and Telemonitoring

Sept 19, 2014
Transparency Life Sciences today announced that it is applying its expertise in crowdsourcing and digital telemonitoring technology to conduct a clinical trial of Auven Therapeutics’ KIACTA in patients with sarcoidosis, a rare systemic inflammatory disease.
Read the full press release

Auven Therapeutics And Bellus Health Announce Completion of Enrollment in the Phase III Confirmatory Study of KIACTA for the Treatment of AA Amyloidosis

May 27, 2014
Auven Therapeutics and BELLUS Health Inc. today announced that the KIACTA Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients.
Read the full press release

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

May 19, 2014
ADC Therapeutics (ADCT) announced today that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Read the full press release

Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA

May 7, 2014
Auven Therapeutics and BELLUS Health Inc. (TSX:BLU) today announced that Lazard has been engaged as financial advisors to explore the sale of KIACTA, an orphan drug nearing completion of its confirmatory Phase III trial as a treatment for AA Amyloidosis.
Read the full press release

Auven Therapeutics and BELLUS Health Announce Licence Agreement with Mount Sinai for KIACTA in Sarcoidosis

May 2, 2014
Auven Therapeutics has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which Auven obtains rights to develop KIACTA (eprodisate) as a treatment for chronic sarcoidosis.
Read the full press release